Cullinan Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Regulation FD disclosureOct 1 →Insiders2 insiders bought $13.3M in 8 open-market buys. 5 insiders sold $1.6M, 13 of 25 sales on a 10b5-1 plan.→HoldersMPM Bioimpact 15.1%Lynx1 13.9%BVF Inc/il 8.9%→Financing →PeersClosest companies: RLAY, BDTX, TYRA→
From the filings
Figures
- Net income
- −$204.7Mlast 12 months
- Operating cash flow
- −$178.6Mlast 12 months
- Cash and equivalents
- $78.6Mat the last balance sheet
- Shares outstanding
- 64.3M shareson issue